CSF3 and aplastic anemia: It was reported by the International Association for Studying Agranulocytosis and Aplastic Anemia that 4% of the patients can develop agranulocytosis, that is, significantly reduced neutrophil counts up to a year following the acute phase of illness [3]. However, there is limited information about the use of filgrastim (granulocyte colony-stimulating factor (G-CSF)) to induce a rise in neutrophil levels, for it to be considered in the management of EBV-induced agranulocytosis [3].